News for Immatics N.V. (IMTX)

Immatics (NASDAQ: IMTX) to present IMA203 TCR T-cell therapy data at the 2025 ASCO Annual Meeting. Oral presentation will include updated data from the

**media[603316]**

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds.

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds.

Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Read why IMTX is a Hold.

**media[578184]**

We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Immatics N.V.

Immatics (IMTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Immatics N.V. targets cancer with its promising IMA203 pipeline. Learn why IMTX stock may be worth waiting for, despite solid data and a strong financial position.

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immatics (IMTX) delivered earnings and revenue surprises of 55.56% and 216.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[468977]**

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Tod

**media[460694]**

Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aileron Therapeutics, Inc. (ALRN) experienced a notable stock movement with a 6.19% decline in its share price. The shares are now trading at $3.87 with a tradi

Japan-based BloomZ Inc. (BLMZ) is up over 95 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund holdings.